Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled CHF10073 in Healthy Volunteers
NCT06746064Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CHF10073 in pulmonary fibrosis (PF), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Adverse events and adverse drug reactions at 17 weeks, Systolic and diastolic Blood Pressure at 42 days and 8 more. Started Jan 2025; status: completed.
02
Drugs
CHF10073
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06746064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746064.